Balancing Risks: SGLT2s, GLP-1s, and the Hip Fracture Patient

In this episode of Hipcast, we speak with three clinical experts about the complexities of surgical timing in hip fracture patients who are taking SGLT2 inhibitors and GLP-1 receptor agonists.Professor Jacqueline Close (Consultant Geriatrician, Prince of Wales Hospital / Neuroscience Research Australia), A/Prof Katherine Tonks (Endocrinologist, Sydney Endocrinology / St Vincent’s Hospital) and Dr Louisa Lowes (Anaesthetist and Director of Perioperative Medicine, Prince of Wales Hospital) share insights from their respective disciplines on balancing surgical urgency with medication-related risks.The discussion explores:Mechanisms and perioperative considerations of SGLT2 inhibitors and GLP-1 agonistsHow these agents influence timing and safety of hip fracture surgeryInterdisciplinary strategies to minimise perioperative complicationsPractical take-aways for clinicians🔗 Resources mentioned:Australian Diabetes Society (ADS):Peri-operative Management of Diabetes MedicationsANZCA Safety Alert: ALERT UPDATE May 2023 Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Use In People with DiabetesANZCA Safety Alert: Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures.Australian and New Zealand Hip Fracture Registry (ANZHFR):Clinical Care Standards and Annual ReportA/Prof Katherine Tonks resource: Is your patient on a SGLT-2 Inhibitor?ANZCA Patient Instructions: Preparing for your medical procedure when taking some diabetes and/or weight loss medications🎙️ Hipcast is hosted by Dr Niamh Dove and produced by the Australian and New Zealand Hip Fracture Registry, dedicated to improving outcomes and experiences for people with hip fracture and those who care for them.